Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease - Wikidata - awgldk - TriplyDB

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

http://www.wikidata.org/entity/Q28196818

about

sameAs

Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor Aspirin and clopidogrel resistance: an emerging clinical entity Aspirin resistance and its implications in clinical practice Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke Oral antiplatelet therapy and percutaneous coronary intervention The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Eptifibatide: The evidence for its role in the management of acute coronary syndromes.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention.Safety of low-dose aspirin in endovascular treatment for intracranial atherosclerotic stenosis.The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease Antiplatelet therapy in secondary stroke prevention--state of the art Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).Aspirin for the prevention of colorectal cancer Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies.Tirofiban for the treatment of ischaemic stroke.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction.Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes.Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke.Antithrombotic medication for stroke prevention.Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review).Antiplatelet therapy in acute coronary syndromes.The evolution of antiplatelet therapy in cardiovascular disease.Optimal aspirin dose in acute coronary syndromes: an emerging consensus.P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.Update of secondary stroke prevention.Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry.Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.Neuropsychological state of the population living in the Aral Sea region (zone of ecological crisis).Acute secondary stroke prevention trials in minor stroke/TIA: prime time for magnetic resonance imaging.

P2860

Q22306433-63587831-3F2F-4A12-B144-0F8003E35A5E Q28183647-8681A05E-BE26-4220-8E67-ED9D3A8C81C0 Q28194021-9153D138-2E0B-4DCD-B8CC-1E0BE936EC06 Q28194069-1EBD54E3-B48E-4992-9913-6137D110CA83 Q28200895-AF9EC0FD-FDE1-4220-8164-83AE963B6592 Q28211452-CAF22EC5-AE71-47D7-9EA2-71A5D4C3B685 Q28217724-68C81CF8-5523-4A67-87FE-E876B9491D59 Q33387192-2FF94760-163D-4141-8080-6FB4EAAE87A0 Q33391279-1CF4D7BB-6C65-4A49-99F8-50C60E4396C9 Q33434702-C3DB3779-5C7E-4DCB-A411-9761447CD7D0 Q33572281-1A47601E-B0B3-4660-8BF4-F10664CDBB84 Q33810226-B60BE179-2A06-4C40-BF04-A33F28AD1A87 Q34075412-77843794-9AAF-4F0F-A27A-30C79F9FC614 Q34175429-D8D5A2DF-5E13-4297-9C2F-BCA015259862 Q35216412-FC522DF1-89A7-49AC-A006-38D1FEB0AD67 Q35851558-E70F28E0-77FC-4721-8FBE-4039E98B3A46 Q35967304-AB512952-73BA-4A80-A409-B25DF65C65C6 Q36040667-7D8F561F-F257-476B-8B76-F27E0C325C4A Q36349613-66DF3817-C907-4E0B-92DC-151B6B258E4F Q36374457-CC0862FB-73C5-4941-B97C-7FB063BCEDC7 Q36587083-0AF88B2C-412A-4A5D-891A-707EC9F99026 Q36799847-5F0903D9-4B16-40B6-9E66-9AE7648B6629 Q37175915-0B8791C7-01A3-4033-BF9E-6C7C6086BE96 Q37532590-7D94075C-4F63-4270-9BF2-05FA86870563 Q37611046-9842040C-3BD0-4191-A7FC-E055F3D8CF54 Q37708482-142DA92E-0D78-4432-9202-8FC6D87DF620 Q37798110-E474B394-56E9-47E1-B318-CE9BF0F0EB2F Q37900470-3F9ECBA6-5A42-49F7-9B1A-A58A90A378DC Q38206844-141AF804-8CBD-41CD-A506-3AC5CFCD9719 Q38420789-7AA10C43-385A-4B94-AC41-5D261B5E3745 Q43078028-7487CDB0-A74D-47BB-9403-4592ACEC78F1 Q44986216-4B1277FF-BFA0-47BB-A0E8-1742FA145241 Q45754526-EBBD8FF1-2BFB-47A3-8B07-51C0556DE57A Q46427553-3FDDE614-1D4D-4465-AD6C-B9E64D506E4A Q46591692-5FA1C1C1-6A44-44D6-9B8A-E3DB24705094 Q47649268-7D94F1C3-782C-40C0-B9D9-DEDD0744B165 Q48966112-B34172A1-41E0-4BE8-93E8-0246FE847B83

P2860

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

http://www.wikidata.org/entity/Q28196818

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@ast

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@en

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@nl

type

label

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@ast

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@en

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@nl

prefLabel

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@ast

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@en

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@nl

P1433

Q28196818-13195D0E-52AE-4F65-8799-8D4748FE1A53

P1476

Q28196818-10C7D422-7556-42F5-9F5B-CED923E02327

P2093

Q28196818-347B85A3-8820-4FFA-B365-ED46BDE58145

Q28196818-454A00E7-BF40-49CC-B839-25772714379D

Q28196818-592EE3F4-2270-4B87-9C4A-65F27950AF51

Q28196818-5B1FACF3-494A-49E7-ACA7-DDEC28431035

Q28196818-5F8CC43A-0CE8-487D-9FBE-BDA4030C6718

Q28196818-7449D1A7-B4B8-4417-82A0-D6BACC73C0F8

Q28196818-A27EE1FE-791A-4ECB-A1F3-342FC5303278

Q28196818-AC171C80-E11E-434B-A482-87E2F60BA7A3

Q28196818-CD0A498E-22FA-4365-94D0-C0AFE067794D

Q28196818-D52DFA80-5D1A-409A-8FC2-65147A0C8758

P304

Q28196818-10D104B0-C0FA-4351-AF3D-B9B8CE581478

P31

Q28196818-425C1F54-C781-4CAB-B36F-5971DD809C49

P356

Q28196818-1DA2F6B0-FBAA-4B7C-8D99-C0EA6B2F593C

P407

Q28196818-72687D7D-7E12-416F-9DFF-D6C2DF691C68

P433

Q28196818-B693A5F6-FB67-47CD-9E27-57C5C355C726

P478

Q28196818-5FA5C2B5-C1E7-43DF-A1D9-FFDACBF0ACCE

P50

Q28196818-26D4059D-99EC-40F2-8476-FB15A767D33C

Q28196818-6B587595-B1DC-4571-99F9-D563FAC277FA

Q28196818-C0E89043-BDDD-423F-930C-B778E533AEAC

Q28196818-CA0CA5E0-748F-4894-8C16-218696A0DB6E

P577

Q28196818-450CD8B2-51FB-4D38-89AB-329096FE5E14

P5875

Q28196818-677CC18A-96BC-46A8-94BE-1F5E86A5DA07

P698

Q28196818-3255DC91-D11E-4CCC-BAD9-B79E8D7A537B

P921

Q28196818-073732A2-C3A6-4609-965D-8D4074082B65

P356

01.CIR.0000084501.48570.F6

P1433

P1476

Randomized, double-blind, plac ...... ry and cerebrovascular disease

@en

P2093

Ashfaq Shuaib

http://www.w3.org/2001/XMLSchema#string

Carmen Graffagnino

http://www.w3.org/2001/XMLSchema#string

Desmond Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Donald Easton

http://www.w3.org/2001/XMLSchema#string

Hans-Christophe Diener

http://www.w3.org/2001/XMLSchema#string

James Ferguson

http://www.w3.org/2001/XMLSchema#string

James T Willerson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Granett

http://www.w3.org/2001/XMLSchema#string

Karen Pieper

http://www.w3.org/2001/XMLSchema#string

Kristina Sigmon

http://www.w3.org/2001/XMLSchema#string

P304

399-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000084501.48570.F6

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Frans Van de Werf

Robert A Harrington

P577

2003-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10651035

http://www.w3.org/2001/XMLSchema#string

P698

12874182

http://www.w3.org/2001/XMLSchema#string

P921